Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
Open Access
- 8 January 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2661-2671
Abstract
Aims: This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide. Materials and methods: This was a retrospective cohort study using Optum's de‐identified Clinformatics Data Mart (Optum CDM) from 1 January 2007 through 30 September 2024. New initiators of semaglutide or dulaglutide ≥18 years with both T2D and ASCVD were included. The index date was the first date of a prescription claim for semaglutide or dulaglutide within the index medication identification period (1 January 2018 through 31 March 2024). The primary outcome was 3‐point MACE (stroke, myocardial infarction [MI], cardiovascular [CV]‐related death). Entropy balancing was applied to balance baseline characteristics. Weighted incidence rates per 1000 person‐years and doubly robust Cox proportional hazard ratios were reported. Results: There were 75 243 enrolees included (semaglutide, 42 007; dulaglutide, 33 236). The mean age was 68.2 and 69.3 years (unweighted) in the semaglutide and dulaglutide cohorts, respectively. After balancing, standardized mean differences were p < 0.001). Conclusions: Among United States Medicare Optum CDM enrolees with T2D and ASCVD, semaglutide was associated with reduced risks of CV outcomes compared with dulaglutide. These results help to address an important evidence gap in selecting glucagon‐like peptide‐1 receptor agonists for this high‐risk population.Keywords
Funding Information
- Novo Nordisk
This publication has 24 references indexed in Scilit:
- Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVDCurrent Medical Research and Opinion, 2025
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 DiabetesJAMA Network Open, 2025
- Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVDDiabetes Research and Clinical Practice, 2025
- Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular diseaseAmerican Journal of Preventive Cardiology, 2025
- Large Sample Properties of Entropy Balancing Estimators of Average Causal EffectsEconometrics and Statistics, 2023
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristicsAmerican Heart Journal, 2023
- Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registryAmerican Heart Journal, 2023
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 DiabetesJACC, 2020
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsJACC, 2018
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016